Diabetes Care (2006), 29: 1269-74
Hermansen K. et al.A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes

Diabetes, Obesity and Metabolism (2006), 8: 58-66
Garber AJ et al.Attainment of glycaemic goals in type 2 diabetes with once-,twice-, or thrice-daily dosing with biphasic insulin aspart 70/30(The 1-2-3 study)

Diabetes Care (2005) 28: 2372-2377
Hershey T et al. Frequency and Timing of Severe Hypoglycemia Affects Spatial Memory in Children With Type 1 Diabetes

Diabetes Care (2005) 28: 1594-1598
Kim C et al. Is Physician Gender Associated With the Quality of Diabetes Care?

Diabetes Care (2005) 28: 1599-1603
Sullivan PW et al. Obesity, Inactivity, and the Prevalence of Diabetes and Diabetes-Related Cardiovascular Comorbidities in the U.S., 2000–2002

Diabetes Care (2005) 28: 1107-1112
Plank J et al. A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacok inetic Properties of the Long-Acting Insulin Analog Detemir

Diabetes Care (2005), 28: 260-65
Raskin P et al. Initiating Insulin Therapy in Type 2 Diabetes. A comparison of biphasic and basal insulin analogs

Diabetes Care (2004) 27: 2676-2681
Stern MP et al. Does the Metabolic Syndrome Improve Identification of Individuals at Risk of Type 2 Diabetes and/or Cardiovascular Disease?

Diabetes Care (2004) 27: 1535-1540
Brown JB et al. The Burden of Treatment Failure in Type 2 Diabetes

Diabetes Care (2004) 27: 1265-1270
Rosenstock J et al. Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study

Diabetes Care (2004), 27: 1706-11
Laesen JL et al. Pancreas Transplantation Improves Vascular Disease in Patients With Type 1 Diabetes

Diabetes Care (2004), 27: 538-546
McKeown K et al. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort

Diabetologia (2004), 47:622-29
Hermansen K et al.: Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes

Diabetes Care (2004), 27: 978-983
Liao Y et al. Critical evaluation of Adult Treatment Panel III Criteria in identifying insulin resistance with dyslipidemia

Diabetes Care (2003), 26: 590-596
Vague P et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

Diabetes Care (2003), 26: 2238-2243
Schwartz S et al. Insulin 70/30 Mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis

Diabetes Care (2005), 28: 2289-2304
Kahn R et al. The Metabolic Syndrome: Time for a Critical Appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

Diabetes Care (2005), 28: 1245-1249
American Diabetes Association Workgroup on Hypoglycemia: Defining and Reporting Hypoglycemia in Diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia

Diabetes Care (2005), 28: 736-744
Padwal R et al. A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes

Diabetes (2005); 54: 1-7
A. Ceriello. Postprandial Hyperglycemia and Diabetes Complications. Is It Time to Treat?

Diabetologia (2004), 47:1895–1905
Siebenhofer A. et al. Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy.

Clin Drug Invest 2004; 24: 695-717. Copyright Adis International, UK. Published with permission.
A. Haycox. Insulin aspart. Evidence-based medicine review.

Insulin Treatment. Insulin Detemir as a Basal Insulin.
Geremia B. Bolli. Textbook of Diabetes. Pickup and Williams; 3rd edition (2004)

Diabetes Care (2004), 27: 1798-1811
Alberti G et al. Type 2 Diabetes in the Young: The Evolving Epidemic: The International Diabetes Federation Consensus Workshop

Diabetes Care (2004), 27: 2067-73
American Diabetes Association. ADA Statement: Weight Management Through Lifestyle Modification for the Prevention and Management of Type 2 Diabetes: Rationale and Strategies: A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition

Diabetes Care (2004), 27: 553-591
Clement S et al. Management of diabetes and hyperglycemia in hospitals
Yale Protocol
Adapted from: Implementation of a safe and effective insulin infusion protocol in a medical intensive unit. Diabetes Care 2004, 27, 461-467